Anika Therapeutics, Inc. Current Federal Tax Expense (Benefit)
Anika Therapeutics, Inc. (ANIK) reported Current Federal Tax Expense (Benefit) of $176.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-03
- Anika Therapeutics, Inc. current federal tax expense (benefit) for fiscal 2025 was $176.00K, a 95.65% decline from fiscal 2024.
- Anika Therapeutics, Inc. current federal tax expense (benefit) for fiscal 2024 was $4.04M, a 17.64% decline from fiscal 2023.
- Anika Therapeutics, Inc. current federal tax expense (benefit) for fiscal 2023 was $4.91M, a 38.00% increase from fiscal 2022.
- Anika Therapeutics, Inc. current federal tax expense (benefit) for fiscal 2022 was $3.56M, a 620.24% increase from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $176.00K 10-K · filed 2026-03-03 | |
| 2024-12-31 | $4.04M 10-K · filed 2026-03-03 | |
| 2023-12-31 | $4.91M 10-K · filed 2026-03-03 | $3.15M 10-K · filed 2024-03-15 |
| 2022-12-31 | $3.56M 10-K · filed 2025-03-17 | $1.00M 10-K · filed 2023-03-16 |
| 2021-12-31 | $494.00K 10-K · filed 2024-03-15 | |
| 2020-12-31 | $357.00K 10-K · filed 2023-03-16 | |
| 2019-12-31 | $6.25M 10-K · filed 2022-03-11 | |
| 2018-12-31 | $4.78M 10-K/A · filed 2021-04-26 | |
| 2017-12-31 | $12.61M 10-K · filed 2020-03-06 | |
| 2016-12-31 | $14.98M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $14.57M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $18.30M 10-K · filed 2017-02-24 | $18.30M 10-K · filed 2015-03-13 |
| 2013-12-31 | $8.02M 10-K · filed 2016-03-10 | $8.02M 10-K · filed 2014-03-13 |
| 2012-12-31 | $7.59M 10-K · filed 2015-03-13 | |
| 2011-12-31 | $3.33M 10-K · filed 2014-03-13 | |
| 2010-12-31 | $1.06M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |